P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Refractory Hodgkin Lymphoma: Time for Targeted Therapies?
TL;DR: Positive results are reported using targeted therapy for salvage treatment before autotransplantation in classical Hodgkin lymphoma.
Journal ArticleDOI
Brigatinib in patients with ALK‐positive anaplastic large cell lymphoma who have failed brentuximab vedotin
Layla Veleanu,Bruno M. Tesson,Laurence Lamant,Ambroise Marçais,Julie Bruneau,Sophie Kaltenbach,Chantal Brouzes,Josquin Moraly,Patrick Villarese,Ludovic Lhermitte,Mehdi Latiri,Adrien Chauchet,Caroline Delette,S. Grosleron,Elise Toussaint,Quentin Cabrera,Pauline Brice,François-Xavier Gros,Aline Clavert,Lucie Oberic,M. Le Goff,Sophie Cereja,Fabienne Meggetto,Elisabeth Macintyre,Vahid Asnafi,David Sibon +25 more
TL;DR: Sibon et al. as mentioned in this paper generated a patient-derived xenograft (PDX) model from a fresh lymph node biopsy of a 41-year-old man newly diagnosed with ALK+ ALCL.
Journal ArticleDOI
Should Adolescents and Young Adults with Hodgkin Lymphoma be Treated As Children or Adults?
Lucille Lew-Derivry,Pauline Brice,Camille Bigenwald,Judith Landman-Parker,Thierry Leblanc,Florian Chevillon,Nicolas Boissel,Aurélie Cabannes-Hamy +7 more
TL;DR: In this paper , the authors compared the 5-year progression-free survival (PFS) by treatment group, with no significant difference between treatment groups (85% in pediatric vs 86% in adult group, HR=0.84, 95%CI [0.35-2.04], p= 0.005).
Journal ArticleDOI
L’arrivée de l’immunothérapie dans le lymphome de Hodgkin.
Laurent Gilardin,Sandy Amorim,Sophie Bernard,Odonchimeg Ravdan,Catherine Thieblemont,Pauline Brice +5 more
TL;DR: Study of the microenvironment from HL tissue reveal ineffective inflammatory and immune cell infiltrate surrounding Reed-Sternberg cells, involving the Programmed cell Death 1/PD-1)/PD-ligand-1 checkpoint pathways.
Journal ArticleDOI
Actualités thérapeutiques dans le lymphome hodgkinien classique
TL;DR: The usually good prognostic of Hodgkin lymphoma may not let us forget that there are still deaths in patients with refractory or early relapse of the disease, there is still an unmet need is these patients and the search for new drugs is essential.